尽管第二季度收入大幅下滑，Madrigal仍下跌

Madrigal Pharmaceuticals (NASDAQ:MDGL) lost over 12%, marking its biggest intraday drop in more than a year, as Wall Street reacted to the company’s Q2 2024 revenue, which, however, exceeded forecasts significantly.

The liver drugmaker reported $14.6M in revenue for the quarter, well surpassing the $4.25M projected by analysts, according to FactSet consensus. Its bottom line, despite indicating a loss of $7.10 per share, also beat expectations by $0.44. 

MDGL's lead product, Rezdiffra, launched in the U.S. in April as the first FDA-approved therapy for liver disease, nonalcoholic steatohepatitis (NASH), drove revenue generation as the company expanded its coverage to more than 50% of commercial lives.

“We’re off to a strong start with our U.S. launch of Rezdiffra and are encouraged by the high enthusiasm and early demand from physicians and patients, as well as the favorable coverage from payers,” Madrigal (MDGL) CEO Bill Sibold said.

Given the success in the U.S., the company said it plans to directly launch the treatment in Europe, where it is currently undergoing regulatory review, with a decision expected by mid-2025.